After the Halo Fades: How Antibody Discovery Is Returning to Science — and to Systems-Yeast Display Technology Special Topic-Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development

After the Halo Fades: How Antibody Discovery Is Returning to Science — and to Systems

Recent news that the researcher widely described as the "father of China's COVID-19 vaccine" is under investigation for disciplinary and legal violations, and that his National Innovation and Advancement Award has been revoked, has set off wide-ranging discussion in the scientific community. What this episode exposes is not simply a personal reversal of fortune. It raises a deeper question about how biomedical innovation itself should be organized: how should we understand — and build — a biotech innovation system that is genuinely sustainable, verifiable, and systematic? Therapeutic antibodies, as a major branch of biomedicine, are a microcosm of that question. The field's evolution — from reliance on the intuition of star scientists to the construction of standardized, platform-based technology systems — may offer the industry one kind of answer.

The Limits of Conventional Animal Immunization

For decades, animal immunization has been the gold standard for generating therapeutic antibodies, particularly fully human antibodies. The principle is simple enough: a target antigen is injected into an animal, and its sophisticated immune system — through complex clonal selection and affinity maturation — eventually produces antibodies of high specificity and high affinity. Yet the success of this approach rests on several uncertain variables: individual differences between immunized animals; antigen design and immunization strategies that depend largely on the researcher's experience; low-throughput screening; and outcomes that hinge on the expertise of a particular team, are difficult to reproduce, and carry an irreducible element of chance.

Modern Antibody Discovery Technologies

To break through these limits, scientists moved antibody discovery from "in vivo" to "in vitro." This is the paradigm shift introduced by display technologies such as phage display and yeast display. By linking antibody genotype directly to phenotype, these platforms allow researchers to screen a vast antibody repertoire systematically and reproducibly for the molecules they want.

Phage display. At the heart of Phagepro Tech? is the fusion of a gene encoding a foreign peptide or protein to a gene encoding a phage coat protein. As progeny phages assemble, the exogenous molecule is displayed on the virion surface, yielding libraries with diversities of up to tens of billions of clones — in effect, an enormous candidate pool. Repeated rounds of incubation with immobilized target antigen, washing, and amplification (panning) efficiently enrich binders against the target. The core strength of the approach is the exceptional diversity of the library, which makes it particularly adept at discovering antibodies against entirely new or difficult targets — membrane proteins and polysaccharides, for example — starting from scratch.

Yeast display. Here antibodies are displayed on the yeast cell surface. Its defining feature is seamless compatibility with fluorescence-activated cell sorting (FACS), which enables quantitative screening and successive rounds of in vitro affinity maturation — turning the generation of ultra-high-affinity antibodies into a fast, controllable, and predictable process.

What these platforms have fundamentally changed comes down to three things:

● Standardized processes. From library construction and panning to screening, every step follows a standard operating procedure. Different laboratories and different operators can reproduce the same experiment, which greatly improves the verifiability of research findings.

● Rational iteration. Screening conditions — pH, ionic strength, competitor concentration — can be controlled precisely, so that "evolutionary pressure" can be applied deliberately to select antibodies with specific properties, such as high stability or binding at a defined pH.

● Freedom from biological constraints. No animals are needed. Human sequence libraries can be used directly, which removes the need for a later humanization step and sidesteps the immunization problems posed by certain highly conserved or toxic antigens.

In practice, modern antibody discovery is usually a multi-platform collaboration: animal immunization can deliver fully human antibodies already "polished" by the natural immune system; phage display can rapidly explore and uncover antibodies against rare epitopes; and yeast display can precisely optimize the affinity and stability of primary hits.

About Tek Biotech (Tianjin) Co., Ltd.

Tek Biotech (Tianjin) Co., Ltd. has built a comprehensive targeted antibody drug discovery platform on the basis of phage display and yeast display technologies. The company provides scientists worldwide with high-quality development services for therapeutic monoclonal antibodies in formats including scFv, VHH, and Fab, and can generate antibodies with a range of functional and structural characteristics (including but not limited to neutralizing antibodies, conformation-specific antibodies, and cross-reactive antibodies). Tek Biotech also offers a full set of downstream services — antibody expression and validation, antibody humanization design and validation, affinity maturation, and CAR-T candidate sequence design — to meet the drug antibody development needs of clients across the spectrum.